



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,678	06/04/2003	Francesco Tato	4161-2	4826
23117	7590	03/07/2006	EXAMINER	
NIXON & VANDERHYE, PC 901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203			GRAFFEO, MICHEL	
			ART UNIT	PAPER NUMBER
			1614	

DATE MAILED: 03/07/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/088,678

Applicant(s)

TATO ET AL.

Examiner

Michel Graffeo

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 13 February 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 28-30,32,34-42,44,46-56,58-67,71 and 72 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 28-30,32,34-42,44,46-56,58-67,71 and 72 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

## **DETAILED ACTION**

### ***Status of Action***

The Amendment (Filed 13 February 2006) canceled claims 31, 33, 43, 45 and 57 and amended claims 28, 34, 40, 44, 46 and 51-53. Claims 28-30, 32, 34-42, 44, 46-56, 58-67 and 71-72 are pending and examined.

Applicant's arguments, see response, filed 13 February 2006, have been fully considered and are persuasive. However, upon further consideration, a new ground(s) of rejection is made. Any rejection not specifically stated in this Office Action has been withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

### ***New Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of

the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 28-30, 32, 34-42, 44, 46-56, 58-67 and 71-72 are rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0297946 to Fondy et al. in view of Richman et al. Interferon Protects Normal Human Granulocyte/Macrophage Colon-Forming Cells from Ara-C Cytotoxicity. Journal of Biological Response Modifiers. 570-575 (1990), taken together with WO94/12202 to University of Dundee and further in view of Avery Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics (1987) (cited to show the state of the art).

Fondy et al. teach a method of treating cells in vivo (see page 4 lines 35-37) and in vitro (see page 4 lines 43-47) comprising a protective cytochalasin compound such as cytochalasin D (see page 4 lines 25-30) and an antineoplastic agent such as the vinca alkaloids (see page 7 lines 17-24) wherein the components can be administered sequentially (see page 4 lines 48-50).

Fondy et al. state that the cytochalasin and antineoplastic agents can be administered sequentially but do not recite specific examples thereto. As applied below, Richman et al. teach a method of treating normal and malignant cells in vitro comprising a 1 hr pretreatment of a protective compound.

Richman et al. teach a method of treating normal and malignant cells in vitro comprising a 1 hr pretreatment (see Summary) of a protective compound, specifically IFN which is known to block cell cycle progression in normal cells (see introduction page 570), followed by a treatment with Ara-C (cytarabine) resulting in the protection of normal cells (see Results page 572) whereas there is no significant protection of leukemia cells (see Results page 573).

Neither Fondy et al. nor Richman et al. speak directly about tumor cells having an inactive p53 pathway. Nonetheless, Applicant admits on page 5 lines 1-5 of the specification that most tumor cells lack a functional p53 pathway. Additionally, University is cited to show the state of the art at the time the instant application was filed and teaches that mutation of p53 is a very common genetic alteration in human cancers (see page 1 in the background of the invention). Thus these claims would be appropriate for almost any tumor model.

Neither Fondy et al. nor Richman et al. recite the treatment of alopecia specifically, but since alopecia is caused by chemotherapies that are not selective for normal proliferating cells, one skilled in the art would find the treatment of alopecia to be a necessary result of the claimed invention.

Neither Fondy et al. nor Richman et al. teach specific times for multiple rounds of pretreatments and treatments with the claimed method. Nonetheless, one skilled in the art would find it obvious in view of routine optimization to vary the times for pretreatment and washing of the cells in preparation for an additional round of pretreatment and

treatment. Specifically, See Avery pages 1024-1050 and in particular section 2, 3.2 and Table V which all teach an alternating schedule for dosing a chemotherapeutic regime.

One skilled in the art would be motivated to combine Fondy et al. with Richman et al. Both are directed to the specific protection of non-cancerous cells by inhibiting cell cycle progression while targeting proliferating tumor cells. Further, Richman et al. suggest that the protective agent and chemotherapy can be administered sequentially as well as concurrently (see Examples 16 and 17 which show in vitro treatment of cells with ADR which were treated with cytochalasin according to Example 14). Thus, the claimed invention of the composition was within the ordinary skill in the art to make and use at the time it was made and was as a whole, *prima facie* obvious.

### ***Response to Arguments***

Applicant's arguments filed 13 February 2006 have been fully considered but they are not persuasive.

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., a protective compound coated by a controlled release layer and a kit having different components for sequential administration) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Moreover, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention

Art Unit: 1614

and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Therefore, the new rejection is considered proper.

### ***Conclusion***

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michel Graffeo whose telephone number is 571-272-8505. The examiner can normally be reached on 9am to 5:30pm Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

28 February 2006  
MG

mb

  
CHRISTOPHER S. F. LOW  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600